These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27241709)

  • 1. Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.
    Higgins GA; Silenieks LB; Altherr EB; MacMillan C; Fletcher PJ; Pratt WE
    Psychopharmacology (Berl); 2016 Jul; 233(14):2841-56. PubMed ID: 27241709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5-HT
    Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S
    Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evidence for combining the 5-HT
    Fletcher PJ; Li Z; Silenieks LB; MacMillan C; DeLannoy I; Higgins GA
    Addict Biol; 2019 May; 24(3):376-387. PubMed ID: 29498158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of impulsivity and reward in the anti-obesity actions of 5-HT
    Higgins GA; Zeeb FD; Fletcher PJ
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
    Higgins GA; Silenieks LB; Rossmann A; Rizos Z; Noble K; Soko AD; Fletcher PJ
    Neuropsychopharmacology; 2012 Apr; 37(5):1177-91. PubMed ID: 22189292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
    Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies To Examine Potential Tolerability Differences between the 5-HT
    Higgins GA; Silenieks LB; Patrick A; De Lannoy IAM; Fletcher PJ; Parker LA; MacLusky NJ; Sullivan LC; Chavera TA; Berg KA
    ACS Chem Neurosci; 2017 May; 8(5):1074-1084. PubMed ID: 28338324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.
    Higgs S; Cooper AJ; Barnes NM
    Psychopharmacology (Berl); 2016 Feb; 233(3):417-24. PubMed ID: 26507195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 5-HT
    Fletcher PJ; Rahbarnia A; Li Z; Ji X; Higgins GA; Funk D; Lê AD
    Behav Brain Res; 2023 Jun; 447():114438. PubMed ID: 37059187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD; Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1231-40. PubMed ID: 25781911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.
    Neelakantan H; Holliday ED; Fox RG; Stutz SJ; Comer SD; Haney M; Anastasio NC; Moeller FG; Cunningham KA
    ACS Chem Neurosci; 2017 May; 8(5):1065-1073. PubMed ID: 28107783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM; Rice KC; France CP
    J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats.
    Fletcher PJ; Li Z; Ji X; Higgins GA; Funk D; Lê AD
    Neuropharmacology; 2022 Sep; 215():109150. PubMed ID: 35644487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated 7-Day Treatment with the 5-HT
    Banks ML; Negus SS
    Neuropsychopharmacology; 2017 Apr; 42(5):1082-1092. PubMed ID: 27857126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the discriminative stimulus effects of lorcaserin in rats.
    Serafine KM; Rice KC; France CP
    J Exp Anal Behav; 2016 Sep; 106(2):107-16. PubMed ID: 27640338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats.
    Rezvani AH; Cauley MC; Levin ED
    Pharmacol Biochem Behav; 2014 Oct; 125():8-14. PubMed ID: 25109272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
    Levin ED; Johnson JE; Slade S; Wells C; Cauley M; Petro A; Rose JE
    J Pharmacol Exp Ther; 2011 Sep; 338(3):890-6. PubMed ID: 21636655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.
    Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1071-88. PubMed ID: 25870913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.